RT Journal Article
SR Electronic
T1 Disentangling the direct and indirect effects of childhood adiposity on type 1 diabetes and immune-associated diseases: a multivariable Mendelian randomization study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.19.21255222
DO 10.1101/2021.04.19.21255222
A1 Tom G Richardson
A1 Daniel J M Crouch
A1 Grace M Power
A1 Fernanda Morales Berstein
A1 Emma Hazelwood
A1 Si Fang
A1 Yoonsu Cho
A1 Jamie R J Inshaw
A1 Catherine C Robertson
A1 Carlo Sidore
A1 Francesco Cucca
A1 Steven S Rich
A1 John A Todd
A1 George Davey Smith
YR 2021
UL http://medrxiv.org/content/early/2021/04/20/2021.04.19.21255222.abstract
AB Background The rising prevalence of childhood obesity has been postulated as an explanation for the increasing rate of individuals diagnosed with type 1 diabetes (T1D). However, robust causal evidence supporting this claim has been extremely challenging to uncover, particularly given the typical early onset of T1D.Methods In this study, we used genetic variation to separate the direct effect of childhood body size on T1D risk from the effects of body size at different stages in the life course using univariable and multivariable Mendelian randomization (MR). Similar MR analyses were conducted on risk of seven other chronic immune-associated diseases.Findings Childhood body size provided evidence of an effect on T1D (based on a sample of 5,913 cases and 8,282 controls) using a univariable model (OR=2.05 per change in body size category, 95% CI=1.20 to 3.50, P=0.008), which remained after accounting for body size at birth and during adulthood (OR=2.32, 95% CI=1.21 to 4.42, P=0.013). The direct effect of childhood body size was validated using data from a large-scale T1D meta-analysis based on n=15,573 cases and n=158,408 controls (OR=1.94, 95% CI=1.21 to 3.12, P=0.006). We also obtained evidence that childhood adiposity influences risk of asthma (OR=1.31, 95% CI=1.08 to 1.60, P=0.007), eczema (OR=1.25, 95% CI=1.03 to 1.51, P=0.024) and hypothyroidism (OR=1.42, 95% CI=1.12 to 1.80, P=0.004). However, these estimates all attenuated to the null when accounting for adult body size, suggesting that the effect of childhood adiposity on these outcomes is mediated by adiposity in later life.Interpretation Our findings support a causal role for higher childhood adiposity on higher risk of being diagnosed with T1D. In contrast, the effect of childhood adiposity on the other immune-associated diseases studied was explained by a long-term effect of remaining overweight for many years over the life course.Competing Interest StatementJAT is a member of a Human Genetics Advisory Board of GSK. TGR is employed part time by Novo Nordisk outside of this work. All other authors declare no conflict of interest.Funding StatementThis work was supported by the Integrative Epidemiology Unit which receives funding from the UK Medical Research Council and the University of Bristol (MC_UU_00011/1). GDS conducts research at the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. TGR was a UKRI Innovation Research Fellow (MR/S003886/1) whilst undertaking this project. GMP is supported by grant MR/N0137941/1 for the GW4 Biomed Doctoral Training Programme, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI. SF and FMB are supported by Wellcome Trust PhD studentships in Molecular, Genetic and Lifecourse Epidemiology [108902/Z/15/Z & 218495/Z/19/Z respectively]. The work of DJMC, JRJI and JAT was supported by the JDRF [9-2011-253], [5-SRA-2015-130-A-N], [4-SRA-2017-473-A-N]; the Wellcome [091157/Z/10/Z], [107212/Z/15/Z]; [203141/Z/16/Z]. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Computation used the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre. Financial support was provided by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All analyses conducted in this study are based on data from summary-level datasets (whose ethical approval can be found in the corresponding studies referenced) or the UK Biobank study (Research Ethics Committee approval number: 11/NW/0382, app #15825).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of all data analysed in this study has been referenced throughout the manuscript and supplementary materials.